全文获取类型
收费全文 | 8045篇 |
免费 | 794篇 |
国内免费 | 8篇 |
出版年
2023年 | 43篇 |
2022年 | 101篇 |
2021年 | 171篇 |
2020年 | 94篇 |
2019年 | 135篇 |
2018年 | 127篇 |
2017年 | 135篇 |
2016年 | 216篇 |
2015年 | 377篇 |
2014年 | 432篇 |
2013年 | 504篇 |
2012年 | 610篇 |
2011年 | 623篇 |
2010年 | 372篇 |
2009年 | 338篇 |
2008年 | 492篇 |
2007年 | 457篇 |
2006年 | 447篇 |
2005年 | 395篇 |
2004年 | 357篇 |
2003年 | 332篇 |
2002年 | 304篇 |
2001年 | 97篇 |
2000年 | 100篇 |
1999年 | 103篇 |
1998年 | 79篇 |
1997年 | 47篇 |
1996年 | 63篇 |
1995年 | 45篇 |
1994年 | 39篇 |
1993年 | 30篇 |
1992年 | 72篇 |
1991年 | 65篇 |
1990年 | 69篇 |
1989年 | 49篇 |
1988年 | 54篇 |
1987年 | 57篇 |
1986年 | 45篇 |
1985年 | 59篇 |
1984年 | 49篇 |
1983年 | 39篇 |
1982年 | 41篇 |
1981年 | 30篇 |
1980年 | 38篇 |
1979年 | 50篇 |
1977年 | 40篇 |
1975年 | 29篇 |
1974年 | 36篇 |
1973年 | 34篇 |
1967年 | 31篇 |
排序方式: 共有8847条查询结果,搜索用时 15 毫秒
1.
Minh C. Nguyen Guang Huan Tu Kathryn E. Koprivnikar Melissa Gonzalez-Edick Karin U. Jooss Thomas C. Harding 《Cancer immunology, immunotherapy : CII》2010,59(9):1313-1323
A critical factor in clinical development of cancer immunotherapies is the identification of tumor-associated antigens that
may be related to immunotherapy potency. In this study, protein microarrays containing >8,000 human proteins were screened
with serum from prostate cancer patients (N = 13) before and after treatment with a granulocyte–macrophage colony-stimulating factor (GM-CSF)-secreting whole cell immunotherapy.
Thirty-three proteins were identified that displayed significantly elevated (P ≤ 0.05) signals in post-treatment samples, including three proteins that have previously been associated with prostate carcinogenesis,
galectin-8, T-cell alternative reading frame protein (TARP) and TNF-receptor-associated protein 1 (TRAP1). Expanded analysis
of antibody induction in metastatic, castration-resistant prostate cancer (mCRPC) patients (N = 92) from two phase 1/2 trials of prostate cancer immunotherapy, G-9803 and G-0010, indicated a significant (P = 0.03) association of TARP antibody induction and median survival time (MST). Antibody induction to TARP was also significantly
correlated (P = 0.036) with an increase in prostate-specific antigen doubling time (PSADT) in patients with a biochemical (PSA) recurrence
following prostatectomy or radiation therapy (N = 19) from in a previous phase 1/2 trial of prostate cancer immunotherapy, G-9802. RNA and protein encoding TARP and TRAP1
was up-regulated in prostate cancer tissue compared to matched normal controls. These preliminary findings suggest that antibody
induction to TARP may represent a possible biomarker for treatment response to GM-CSF secreting cellular immunotherapy in
prostate cancer patients and demonstrates the utility of using protein microarrays for the high-throughput screening of patient-derived
antibody responses. 相似文献
2.
Shira Weingarten-Gabbay Susan Klaeger Siranush Sarkizova Leah R. Pearlman Da-Yuan Chen Kathleen M.E. Gallagher Matthew R. Bauer Hannah B. Taylor W. Augustine Dunn Christina Tarr John Sidney Suzanna Rachimi Hasahn L. Conway Katelin Katsis Yuntong Wang Del Leistritz-Edwards Melissa R. Durkin Christopher H. Tomkins-Tinch Pardis C. Sabeti 《Cell》2021,184(15):3962-3980.e17
3.
4.
F Stephen Perry 《BMJ (Clinical research ed.)》1998,317(7156):481
5.
Melissa A. Partridge Sumana Gopinath Simon J. Myers Jens R Coorssen 《Journal of chemical biology》2016,9(1):9-18
An initial proteomic analysis of the cuprizone mouse model to characterise the breadth of toxicity by assessing cortex, skeletal muscle, spleen and peripheral blood mononuclear cells. Cuprizone treated vs. control mice for an initial characterisation. Select tissues from each group were pooled, analysed in triplicate using two-dimensional gel electrophoresis (2DE) and deep imaging and altered protein species identified using liquid chromatography tandem mass spectrometry (LC/MS/MS). Forty-three proteins were found to be uniquely detectable or undetectable in the cuprizone treatment group across the tissues analysed. Protein species identified in the cortex may potentially be linked to axonal damage in this model, and those in the spleen and peripheral blood mononuclear cells to the minimal peripheral immune cell infiltration into the central nervous system during cuprizone mediated demyelination. Primary oligodendrocytosis has been observed in type III lesions in multiple sclerosis. However, the underlying mechanisms are poorly understood. Cuprizone treatment results in oligodendrocyte apoptosis and secondary demyelination. This initial analysis identified proteins likely related to axonal damage; these may link primary oligodendrocytosis and secondary axonal damage. Furthermore, this appears to be the first study of the cuprizone model to also identify alterations in the proteomes of skeletal muscle, spleen and peripheral blood mononuclear cells. Notably, protein disulphide isomerase was not detected in the cuprizone cohort; its absence has been linked to reduced major histocompatibility class I assembly and reduced antigen presentation. Overall, the results suggest that, like experimental autoimmune encephalomyelitis, results from the standard cuprizone model should be carefully considered relative to clinical multiple sclerosis. 相似文献
6.
7.
8.
9.
Nataly Mancette Rijensky Netta R. Blondheim Shraga Eilon Barnea Nir Peled Eli Rosenbaum Aron Popovtzer Solomon M. Stemmer Alejandro Livoff Mark Shlapobersky Neta Moskovits Dafna Perry Eitan Rubin Itzhak Haviv Arie Admon 《Molecular & cellular proteomics : MCP》2020,19(8):1360-1374
Highlights
- •Sufficient tumor tissues are often unavailable large HLA peptidome discovery.
- •Using patient derived xenograft (PDX) tumors can overcome this limitation.
- •The large PDX HLA peptidomes expand significantly those of the original biopsies.
- •The HLA peptidomes of the PDX tumors included many tumor antigens.
10.